US insurance company Chubb Ltd has canceled the planned initial public offering (IPO) of its Malaysian unit, Chubb Insurance Malaysia Bhd. The IPO was intended to help Chubb comply with regulatory requirements for foreign insurers to reduce their stakes in local units, but the company is now exploring other options due to unfavorable market conditions. Any future attempt to list would require a complete restart of the regulatory process.
US insurance company Chubb Ltd has canceled the planned initial public offering (IPO) of its Malaysian unit, Chubb Insurance Malaysia Bhd. The IPO was intended to help Chubb comply with a Malaysian regulator's mandate for foreign insurers to reduce their stakes in local units, but the company is now exploring other options due to unfavorable market conditions. Any future attempt to list the unit would require a complete restart of the regulatory process.
American Healthcare REIT, Inc. announced the full exercise of the underwriters' overallotment option for 1,987,500 shares of common stock, which occurred on August 20, 2026. This exercise was followed by the establishment of additional forward sale agreements with Morgan Stanley & Co. LLC, Citigroup Global Markets Inc., and KeyBanc Capital Markets Inc. The proceeds from these transactions are intended for a pending senior housing portfolio acquisition, future investments, and general corporate purposes.
Samos Energy Acquisition Corporation (SAMO), a blank-check company, reported a net loss of $28,393 for its initial operating period from January 27 to March 31, 2026. However, it successfully completed an IPO on July 13, 2026, raising $230 million which has been placed in a Trust Account for its first business combination. The company is actively seeking to acquire cash-generative international energy assets and has sufficient liquidity to cover its operational needs for at least one year.
Trasteel Holding has appointed Alessandro Colombi as its first Head of Investor Relations, a strategic move ahead of its anticipated Nasdaq listing. This new role will be critical as Trasteel prepares for a business combination with Sizzle Acquisition Corp II, with the combined entity expected to trade under the symbol TSTL by the end of 2026. Colombi brings extensive experience from industrial, commodities, and media sectors, including a previous role at Trasteel, to establish and lead the company's investor communications.
American Healthcare REIT (AHR) has secured an additional 1.99 million shares of common stock through the full exercise of underwriters' options following a recent public offering. The company entered into Additional Forward Sale Agreements with Morgan Stanley, Citigroup, and KeyBanc Capital Markets to facilitate this, with settlement expected by August 10, 2028. Proceeds from these shares will be used by AHR's Operating Partnership for a pending acquisition of senior housing properties, future investments, and general corporate purposes.
Wolf Haldenstein Adler Freeman & Herz LLP has filed a securities class action lawsuit against Aardvark Therapeutics, Inc. (NASDAQ: AARD) on behalf of investors who purchased shares between February 13, 2025, and May 14, 2026. The lawsuit alleges that Aardvark misrepresented the safety and prospects of its drug ARD-101, leading to a significant stock price drop after a Phase 3 trial was paused due to safety concerns. Investors who suffered losses have until October 13, 2026, to contact the firm and potentially participate as a lead plaintiff.
Ernst W. Bruderer, an officer at CoastalSouth Bancshares, Inc. (COSO), intends to sell 1,000 shares of common stock valued at $27,888.00 through Raymond James & Associates. The shares were acquired via an IPO purchase in July 2025. A prior sale of 1,000 shares on August 10, 2026, for $27,563.00 was also disclosed in the Rule 144 filing.
Robbins LLP is reminding investors who lost money in Aardvark Therapeutics, Inc. (NASDAQ: AARD) to contact the firm regarding a class action lawsuit. The lawsuit alleges that Aardvark misled investors about the safety and efficacy of its lead drug candidate, ARD-101, which resulted in significant stock drops after a voluntary trial pause and an FDA clinical hold. Investors who purchased AARD stock between February 13, 2025, and May 14, 2026, are urged to seek information about becoming lead plaintiff by October 13, 2026.
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against AEVEX Corp. (NYSE: AVEX) regarding alleged concealment of a pre-arranged plan to override a 180-day lock-up period after its IPO. The lawsuit claims AEVEX and its executives misrepresented that Madison, the sole owner of AEVEX's common stock, would be restricted from selling shares until October 13, 2026, while allegedly planning an early secondary public offering. Investors who purchased AEVEX Class A common stock between April 17, 2026, and June 4, 2026, have until October 20, 2026, to apply for lead plaintiff status.
_07_03_2026_03_50_21_133108.jpg)
